TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer.
Margaux Van Damme, Ximena Elzo-Kraemer, An Deman et al.
✦ AI-curated · Sources linked
Case in brief
A patient with radioiodine-refractory differentiated thyroid cancer developed recurring nephrotic range proteinuria while being treated with lenvatinib, sorafenib, and cabozantinib. The proteinuria was linked to the use of tyrosine kinase inhibitors targeting the VEGF pathway. Early recognition and management led to partial or full reversibility of renal damage, emphasizing the importance of monitoring renal function during treatment.
Diagnostic / clinical pearl
Clinicians should be vigilant for proteinuria and nephrotic syndrome in patients receiving VEGFR-targeted TKIs, as these can lead to significant renal complications.
Why it matters
Understanding the renal risks associated with TKIs is crucial for optimizing patient management and preserving renal function while ensuring effective cancer treatment.